Josh Schimmer
Stock Analyst at Cantor Fitzgerald
(4.47)
# 293
Out of 5,149 analysts
144
Total ratings
55.56%
Success rate
19.21%
Average return
Main Sectors:
Stocks Rated by Josh Schimmer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCKT Rocket Pharmaceuticals | Maintains: Overweight | $8 → $10 | $4.80 | +108.33% | 8 | Feb 27, 2026 | |
| NUVL Nuvalent | Maintains: Overweight | $135 → $140 | $100.22 | +39.69% | 2 | Feb 27, 2026 | |
| JANX Janux Therapeutics | Maintains: Overweight | $150 → $100 | $13.44 | +644.05% | 8 | Feb 27, 2026 | |
| MIRM Mirum Pharmaceuticals | Maintains: Overweight | $95 → $130 | $87.80 | +48.06% | 7 | Dec 8, 2025 | |
| DMAC DiaMedica Therapeutics | Initiates: Overweight | $25 | $7.71 | +224.25% | 1 | Nov 14, 2025 | |
| PVLA Palvella Therapeutics | Maintains: Overweight | $120 → $200 | $131.51 | +52.08% | 1 | Nov 6, 2025 | |
| CABA Cabaletta Bio | Maintains: Overweight | $15 → $30 | $3.25 | +823.08% | 3 | Oct 31, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $100 → $110 | $64.53 | +70.46% | 13 | Oct 30, 2025 | |
| IVVD Invivyd | Initiates: Overweight | $10 | $1.62 | +517.28% | 1 | Oct 6, 2025 | |
| CGON CG Oncology | Reiterates: Overweight | $75 | $60.55 | +23.86% | 5 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $20.02 | - | 3 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $28.13 | -11.13% | 4 | Sep 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $25 | $12.26 | +103.92% | 1 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $11 → $6 | $6.95 | -13.67% | 2 | Jun 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $260 → $280 | $239.22 | +17.05% | 4 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $4.90 | +920.41% | 2 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $20 | $5.47 | +265.63% | 2 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $215 | $263.80 | -18.50% | 5 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $5 | $2.19 | +128.31% | 4 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $6.49 | - | 5 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $30 | $8.87 | +238.22% | 4 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $8.46 | - | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.11 | - | 2 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $90 | $40.12 | +124.33% | 6 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.33 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $147.00 | - | 5 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $64.10 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $7.91 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $5.43 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $114.05 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 | $10.71 | +1,020.97% | 3 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $43.79 | +48.44% | 3 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $43 → $5 | $14.00 | -64.29% | 2 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $11 | $14.10 | -21.99% | 2 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $140 → $130 | $131.14 | -0.87% | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $760 | $766.66 | -0.87% | 2 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $24.45 | -38.65% | 1 | Mar 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $55 | $15.73 | +249.65% | 1 | Feb 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $1.55 | +1,835.48% | 1 | Dec 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $1.13 | - | 4 | Dec 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $8.69 | - | 3 | Feb 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $222 → $250 | $425.85 | -41.29% | 4 | Nov 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $98.07 | - | 2 | Jun 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $78.66 | - | 2 | May 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $4.07 | - | 2 | Mar 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $9.03 | +143.63% | 1 | Nov 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $13.96 | - | 2 | Aug 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $58.53 | - | 1 | Aug 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $95 | $233.86 | -59.38% | 1 | Aug 17, 2017 |
Rocket Pharmaceuticals
Feb 27, 2026
Maintains: Overweight
Price Target: $8 → $10
Current: $4.80
Upside: +108.33%
Nuvalent
Feb 27, 2026
Maintains: Overweight
Price Target: $135 → $140
Current: $100.22
Upside: +39.69%
Janux Therapeutics
Feb 27, 2026
Maintains: Overweight
Price Target: $150 → $100
Current: $13.44
Upside: +644.05%
Mirum Pharmaceuticals
Dec 8, 2025
Maintains: Overweight
Price Target: $95 → $130
Current: $87.80
Upside: +48.06%
DiaMedica Therapeutics
Nov 14, 2025
Initiates: Overweight
Price Target: $25
Current: $7.71
Upside: +224.25%
Palvella Therapeutics
Nov 6, 2025
Maintains: Overweight
Price Target: $120 → $200
Current: $131.51
Upside: +52.08%
Cabaletta Bio
Oct 31, 2025
Maintains: Overweight
Price Target: $15 → $30
Current: $3.25
Upside: +823.08%
BridgeBio Pharma
Oct 30, 2025
Maintains: Overweight
Price Target: $100 → $110
Current: $64.53
Upside: +70.46%
Invivyd
Oct 6, 2025
Initiates: Overweight
Price Target: $10
Current: $1.62
Upside: +517.28%
CG Oncology
Sep 8, 2025
Reiterates: Overweight
Price Target: $75
Current: $60.55
Upside: +23.86%
Sep 8, 2025
Reiterates: Overweight
Price Target: n/a
Current: $20.02
Upside: -
Sep 5, 2025
Reiterates: Overweight
Price Target: $25
Current: $28.13
Upside: -11.13%
Jul 1, 2025
Initiates: Overweight
Price Target: $25
Current: $12.26
Upside: +103.92%
Jun 23, 2025
Downgrades: In-Line
Price Target: $11 → $6
Current: $6.95
Upside: -13.67%
May 2, 2025
Maintains: Outperform
Price Target: $260 → $280
Current: $239.22
Upside: +17.05%
Apr 1, 2025
Reiterates: Overweight
Price Target: $50
Current: $4.90
Upside: +920.41%
Mar 25, 2025
Maintains: Overweight
Price Target: $23 → $20
Current: $5.47
Upside: +265.63%
Feb 20, 2025
Reiterates: Overweight
Price Target: $215
Current: $263.80
Upside: -18.50%
Dec 20, 2024
Downgrades: In-Line
Price Target: $5
Current: $2.19
Upside: +128.31%
Dec 11, 2024
Reiterates: Overweight
Price Target: n/a
Current: $6.49
Upside: -
Oct 8, 2024
Reiterates: Overweight
Price Target: $30
Current: $8.87
Upside: +238.22%
Sep 23, 2024
Downgrades: Neutral
Price Target: n/a
Current: $8.46
Upside: -
Sep 17, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.11
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $90
Current: $40.12
Upside: +124.33%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.33
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $147.00
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $64.10
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.91
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $5.43
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $114.05
Upside: -
Aug 26, 2024
Maintains: Outperform
Price Target: $120
Current: $10.71
Upside: +1,020.97%
Aug 9, 2024
Reiterates: Overweight
Price Target: $65
Current: $43.79
Upside: +48.44%
Nov 10, 2023
Downgrades: In-Line
Price Target: $43 → $5
Current: $14.00
Upside: -64.29%
Jun 6, 2023
Maintains: Outperform
Price Target: $20 → $11
Current: $14.10
Upside: -21.99%
Nov 14, 2022
Downgrades: In-Line
Price Target: $140 → $130
Current: $131.14
Upside: -0.87%
Oct 17, 2022
Downgrades: In-Line
Price Target: $760
Current: $766.66
Upside: -0.87%
Mar 15, 2022
Initiates: Outperform
Price Target: $15
Current: $24.45
Upside: -38.65%
Feb 2, 2021
Initiates: Outperform
Price Target: $55
Current: $15.73
Upside: +249.65%
Dec 29, 2020
Initiates: Outperform
Price Target: $30
Current: $1.55
Upside: +1,835.48%
Dec 9, 2019
Downgrades: In-Line
Price Target: n/a
Current: $1.13
Upside: -
Feb 25, 2019
Upgrades: Outperform
Price Target: n/a
Current: $8.69
Upside: -
Nov 16, 2018
Upgrades: Outperform
Price Target: $222 → $250
Current: $425.85
Upside: -41.29%
Jun 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $98.07
Upside: -
May 8, 2018
Downgrades: In-Line
Price Target: n/a
Current: $78.66
Upside: -
Mar 12, 2018
Downgrades: In-Line
Price Target: n/a
Current: $4.07
Upside: -
Nov 7, 2017
Initiates: Outperform
Price Target: $22
Current: $9.03
Upside: +143.63%
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $13.96
Upside: -
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $58.53
Upside: -
Aug 17, 2017
Initiates: Outperform
Price Target: $95
Current: $233.86
Upside: -59.38%